Organisation
Connexin Signalling Research Group
Research Group
To elucidate the role of connexin and pannexin signalling in health and disease with focus on the liver (VUB team) and the nervous system (UGent team).
Projects
1 - 5 of 5
- H2020: Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessmentFrom1 May 2021 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- H2020: CSA: TWINALT: Twinning towards excellence in alternative methods for toxicity assessmentFrom1 Sep 2020 → 31 Aug 2023Funding: H2020-EU.1.2.- EXCELLENT SCIENCE - Future and Emerging Technologies (FET)
- GEAR: Brussels Liver Research to Valorisation Alliance (B-Liver): Valorisation of VUB’s liver cell biology and toxicology expertise via a consortium focused on liver therapeutics, patient and consumer safety.From1 Jan 2020 → TodayFunding: IOF - technology concept exploration, IOF - mandates
- CONNECT-2-CLINIC: Connexin and pannexin peptidomimetics and nanobodies for the clinical treatment of liver disease.From1 Jan 2020 → 31 Dec 2021Funding: H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
- Human stem cells-on-a-chip: a new 3D platform for drug-induced liver steatosisFrom1 Jan 2017 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 167
- Opinion of the Scientific Committee on Consumer Safety (SCCS) – Revisiono of the opinion on the safety of aluminium in cosmetic products(2015)
Authors: Ulrike Bernauer, Pieter-Jan Coenraads, Gisela Degen, Maria Dusinska, Werner Lilienblum, Andreas Luch, Elsa Nielsen, Thomas Platzek, Suresh Rastogi, Christophe Rousselle, et al.
Pages: 1005-1006 - Hepatic differentiation of mesenchymal stem cells: in vitro strategies.(2011)Series: Methods in Molecular Biology
Authors: Sarah Snykers, Tamara Vanhaecke, Vera Rogiers
Pages: 305-314Number of pages: 10 - DETECTIVE: detection of endpoints and biomarkers for repeated dose toxicity testing using in vitro systems.(2015)Volume: 5
Authors: Steven Wink, Bob Van De Water, Raymond Reif, Hammad Seddik, Regina Stöber, Widera Agata, Jan G. Hengstler, A Limonciel, Paul Jennings, Sylvia Escher, et al.
Pages: 136-165Number of pages: 29 - 3Rs toxicity testing and disease modeling projects in the European Horizon 2020 research and innovation program(2020)
Authors: Mathieu Vinken
Pages: 775-784 - Safety evaluation of traces of nickel and chrome in cosmetics: The case of Dead Sea mud.(2015)
Authors: Ze'evi Ma'or, Ludwik Halicz, Meital Portugal-Cohen, Matteo Z. Russo, Frederica Robino, Tamara Vanhaecke, Vera Rogiers
Pages: 797-801 - Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research(2015)
Authors: Joost Willebrords, Isabel Veloso Alves Pereira, Michael Maes, Sara Crespo Yanguas, Isabelle Colle, Bert Van den Bossche, Tereza Cristina da Silva, Claudia Pinto Marques Souza de Oliveira, Wellington Andraus, Venâncio Avancini Ferreira Alves, et al.
Pages: 106-125 - Adverse outcome pathways: opportunities, limitations and open questions(2017)
Authors: Marcel Leist, Ahmed Ghallab, Rabea Graepel, Rosemarie Marchan, Reham Hassan, Susanne Hougaard Bennekou, Alice Limonciel, Paul Jennings, Mathieu Vinken, Stefan Schildknecht, et al.
Pages: 3477-3505 - Adverse outcome pathways and drug-induced liver injury testing(2015)
Authors: Mathieu Vinken
Pages: 1391-1397 - Experimental models of hepatotoxicity related to acute liver failure(2016)
Authors: Michael Maes, Mathieu Vinken, Hartmut Jaeschke
Pages: 86-97 - Omics-based input and output in the development and use of adverse outcome pathways.(2019)
Authors: Mathieu Vinken
Pages: 8-12